Press coverage about ProQR Therapeutics (NASDAQ:PRQR) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.99524438384 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of ProQR Therapeutics (NASDAQ:PRQR) opened at $2.80 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.72 and a current ratio of 6.72. ProQR Therapeutics has a twelve month low of $2.75 and a twelve month high of $6.90.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. analysts forecast that ProQR Therapeutics will post -1.71 EPS for the current year.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 30th. Leerink Swann reaffirmed an “outperform” rating and issued a $12.00 price objective (up previously from $10.00) on shares of ProQR Therapeutics in a report on Tuesday, September 26th. JMP Securities increased their price objective on shares of ProQR Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics in a report on Sunday, September 17th. Finally, ValuEngine cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $18.88.

TRADEMARK VIOLATION WARNING: “ProQR Therapeutics (PRQR) Earns Daily Media Sentiment Rating of 0.13” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Insider Buying and Selling by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with's FREE daily email newsletter.